Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services

JAMA Internal Medicine

Volumn 176, Issue 1, 2016, Pages 75-84

  Liu, Albert Y ^a,b   Cohen, Stephanie E ^a,b   Vittinghoff, Eric ^b   Anderson, Peter L ^c   Doblecki Lewis, Susanne ^d   Bacon, Oliver ^a,b   Chege, Wairimu ^e   Postle, Brian S ^f   Matheson, Tim ^a   Rivet Amico, K ^g   Liegler, Teri ^b   Keith Rawlings, M ^h   Trainor, Nikole ^a   Blue, Robert Wilder ^a   Estrada, Yannine ^d   Coleman, Megan E ⁱ   Cardenas, Gabriel ^d   Feaster, Daniel J ^d   Grant, Robert ^j,k   Philip, Susan S ^a,b   Elion, Richard ^i,l   Buchbinder, Susan ^a,b   Kolber, Michael A ^d   more..

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f DF/Net Research   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ Whitman Walker Institute   (United States)

^j GLADSTONE INSTITUTES   (United States)

^k SAN FRANCISCO AIDS FOUNDATION   (United States)

^l GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ORGANOPHOSPHATE; TENOFOVIR; TENOFOVIR DIPHOSPHATE;

ADULT; AFRICAN AMERICAN; ARTICLE; CHLAMYDIASIS; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DRIED BLOOD SPOT TESTING; FEMALE; FEMALE TO MALE TRANSGENDER; FOLLOW UP; GONORRHEA; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PUBLIC HEALTH; SEXUAL BEHAVIOR; SEXUAL HEALTH SERVICE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SYPHILIS; TREATMENT DURATION; UNITED STATES; ADOLESCENT; ANALOGS AND DERIVATIVES; BISEXUALITY; BLOOD; CALIFORNIA; CHLAMYDIA INFECTIONS; COMMUNITY CARE; DISTRICT OF COLUMBIA; FLORIDA; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; REPRODUCTIVE HEALTH; STATISTICS AND NUMERICAL DATA; TRANSGENDER; UNSAFE SEX; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BISEXUALITY; CHLAMYDIA INFECTIONS; COMMUNITY HEALTH SERVICES; DISTRICT OF COLUMBIA; FEMALE; FLORIDA; GONORRHEA; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOPHOSPHATES; PRE-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; REPRODUCTIVE HEALTH; SAN FRANCISCO; SEXUAL BEHAVIOR; SYPHILIS; TENOFOVIR; TRANSGENDER PERSONS; UNSAFE SEX; YOUNG ADULT;

EID: 84954562396     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.4683     Document Type: Article

References (50)

1. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
4. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Published July 16, 2012. Accessed August 12, 2015.
5. McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD Study. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2015; February 24, 2015; Seattle, WA. Abstract 22LB.
6. Molina JM, Capitant C, Spire B, et al. On Demand PrEP with oral TDF-FTC in MSM: results of the ANRS IPERGAY Trial. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2015; February 24, 2015; Seattle, WA. Abstract 24LB.
7. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2013. HIV Surveillance Report, Vol. 25. http://www.cdc.gov/hiv/pdf/g-l/hiv-surveillance-report-vol-25.pdf. Published February 2015. Accessed May 3, 2015.
8. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613. doi:10.1371/journal.pmed.1001613.
9. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548-555.
10. Blumenthal J, Haubrich RH. Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor. 2014;16(11): 909-915.
11. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-F19.
12. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12): 1265-1270.
13. Siemieniuk RA, Bogoch II. Preexposure prophylaxis for HIV infection. N Engl J Med. 2015; 372(18):1767-1768.
14. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr. 2010; 53(4):537-543.
15. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86-94.
16. Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66 (5):530-537.
17. Grant RM, Anderson PL, McMahan V, et al; iPrEx Study Team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
18. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384-390.
19. Mimiaga MJ, Reisner SL, Vanderwarker R, et al. Polysubstance use and HIV/STD risk behavior among Massachusetts men who have sex with men accessing Department of Public Health mobile van services: implications for intervention development. AIDS Patient Care STDS. 2008;22(9): 745-751.
20. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.
21. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352(18):1873-1883.
22. Liegler T, Abdel-Mohsen M, Bentley LG, et al; iPrEx Study Team. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014; 210(8):1217-1227.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
24. Ananth CV, Kleinbaum DG. Regression models for ordinal responses: a review of methods and applications. Int J Epidemiol. 1997;26(6):1323-1333.
25. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP Demonstration Project. J Acquir Immune Defic Syndr. 2015;68(4): 439-448.
26. Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
27. Marrazzo JM, Ramjee G, Richardson BA, et al; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-518.
28. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014; 59(suppl 1):S55-S60.
29. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7 (6):542-548.
30. Liu A, Glidden DV, Anderson PL, et al; iPrEx Study Team. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;67(5):528-537.
31. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-348.
32. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541-550.
33. Kessler J, Myers JE, Nucifora KA, et al. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York City. AIDS. 2014;28(18):2683-2691.
34. Castillo-Mancilla JR, Seifert S, Zheng J, et al. Population pharmacokinetics of tenofovir-diphosphate in red blood cells in HIV-negative and HIV-infected adults. Rev Antiviral Ther Infect Dis. 2014;4:24-25.
35. Dale SK, Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV [published online October 7, 2014]. J Health Psychol. doi:10.1177/1359105314551950.
36. Thames AD, Moizel J, Panos SE, et al. Differential predictors of medication adherence in HIV: findings from a sample of African American and Caucasian HIV-positive drug-using adults. AIDS Patient Care STDS. 2012;26(10):621-630.
37. Blackstock OJ, Addison DN, Brennan JS, Alao OA. Trust in primary care providers and antiretroviral adherence in an urban HIV clinic. J Health Care Poor Underserved. 2012;23(1):88-98.
38. Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 Study. J Acquir Immune Defic Syndr. 2012;60(5):466-472.
39. Osborn CY, Cavanaugh K, Wallston KA, et al. Health literacy explains racial disparities in diabetes medication adherence. J Health Commun. 2011;16 (3)(suppl 3):268-278.
40. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014;129(7):754-763.
41. Dickson VV, Knafl GJ, Wald J, Riegel B. Racial differences in clinical treatment and self-care behaviors of adults with chronic heart failure. J Am Heart Assoc. 2015;4(4):pii: e001561. doi:10.1161/JAHA.114.001561.
42. Rose LE, Kim MT, Dennison CR, Hill MN. The contexts of adherence for African Americans with high blood pressure. J Adv Nurs. 2000;32(3):587-594.
43. Shi L, Stevens GD. Vulnerability and unmet health care needs: the influence of multiple risk factors. J Gen Intern Med. 2005;20(2):148-154.
44. Liu A. Developing and implementing a mobile health (mHealth) adherence support system for HIV-uninfected men who have sex with men (MSM) taking pre-exposure prophylaxis (PrEP): the iText Study. Paper presented at: 8th International Conference on HIV Treatment and Prevention Adherence; June 3, 2013; Miami, FL. Abstract 229.
45. Molina JM, Pintado C, Gatey C, et al. Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? BMC Med. 2013;11:186. doi:10.1186/1741-7015-11-186.
46. Scott H, Vittinghoff E, Irvin R, et al. Sex Pro: a personalized HIV risk assessment tool for men who have sex with men. Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2015; February 24, 2015; Seattle, WA. Abstract 1017.
47. Vallabhaneni S, Hartogensis W, Sheon N, et al. Harnessing mobile health technology in HIV research: a pilot study utilizing a smartphone-based daily-diary app to collect event-level sexual activity data. Poster presented at: seventh IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2, 2013; Kuala Lampur, Malaysia. Abstract TUPE358.
48. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed May 3, 2015.
49. Sevelius J. Pre-exposure prophylaxis (PrEP) and trans people: what do we know now; what else do we need to understand in order to add this promising intervention into our prevention toolkit? Paper presented at: 2015 National Transgender Health Summit; April 18, 2015; Oakland, CA.
50. Cohen SE, Vittinghoff E, Doblecki-Lewis S, et al. Response to "Race and the public health impact potential of PrEP in the United States" [published online June 3, 2015]. J Acquir Immune Defic Syndr. doi:10.1097/QAI.0000000000000716.